GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Nexwise Intelligence China
301248
5
Astro-century Education & Technology
300654
US Stock MarketDetailed Quotes
DAWN Day One Biopharmaceuticals
- 12.510
- +0.130+1.05%
Close Jan 23 16:00 ET
- 12.590
- +0.080+0.64%
Post 20:01 ET
1.26BMarket Cap-12.90P/E (TTM)
12.515High12.150Low1.03MVolume12.300Open12.380Pre Close12.70MTurnover1.48%Turnover RatioLossP/E (Static)100.85MShares18.07052wk High2.27P/B868.40MFloat Cap11.13052wk Low--Dividend TTM69.42MShs Float28.699Historical High--Div YieldTTM2.95%Amplitude5.440Historical Low12.388Avg Price1Lot Size
About Day One Biopharmaceuticals Company
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
Company Profile
SymbolDAWN
Company NameDay One Biopharmaceuticals
Listing DateMay 27, 2021
Issue Price16.00
Founded2018
CEODr. Jeremy Bender
MarketNASDAQ
Employees155
Fiscal Year Ends12-31
Address2000 Sierra Point Parkway,Suite 501
CityBrisbane
ProvinceCalifornia
CountryUnited States of America
Zip Code94005
Phone1-650-484-0899
Websitehttp://www.dayonebio.com
Company Executives
- Name
- Position
- Salary
- Dr. Jeremy Bender
- Chief Executive Officer, President and Director
- 6.91M
- Charles N. York, II
- Principal Accounting Officer, Chief Operating Officer, Chief Financial Officer and Secretary
- 3.55M
- Adam Dubow
- General Counsel and Chief Compliance Officer
- 2.77M
- Garry A. Nicholson
- Chairman of the Board
- 383.38K
- Dr. William Grossman
- Director
- --
- Habib Joseph Dable
- Director
- --
- Michael Gladstone
- Independent Director
- 342.88K
- Scott Garland
- Independent Director
- 342.88K
- Dr. John A. Josey, PhD
- Independent Director
- 350.75K
- Saira Ramasastry, M.Phil,M.S.
- Independent Director
- 351.75K
- Natalie C. Holles
- Lead Independent Director
- 352.50K
- Dr. Samuel Blackman, M.D.
- Head of Research and Development
- 2.49M
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
U.S.-China talks spark interest, no more inflation?
🎙️Discussion: 1. How will Trump's China policies affect Chinese assets? 2. Which sectors might benefit as U.S. inflation risks decline?
Moomoo News Global
Dec 9, 2024 20:23
China Will Adopt a "Moderately Accommodative" Monetary Policy in the Next Year, The First Shift to Easing Since 2011